Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report

Publisher： Karger

E-ISSN： 1423-0356|91|4|327-332

ISSN： 0025-7931

Source： Respiration, Vol.91, Iss.4, 2016-04, pp. : 327-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pirfenidone and inhaled NAC for IPF

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 3, 2015-04 ,pp. : 445-452

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone

By  

Respiration, Vol. 93, Iss. 6, 2017-04 ,pp. : 415-423

Karger

Access to resources Recommend Favorite

Pirfenidone in Idiopathic Pulmonary Fibrosis “RECAP-itulating Safety into the Real World”

By  

Respiration, Vol. 94, Iss. 5, 2017-09 ,pp. : 405-407

Karger

Access to resources Recommend Favorite

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

By  

Respiration, Vol. 92, Iss. 2, 2016-08 ,pp. : 98-106

Karger

Access to resources Recommend Favorite

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases

By  

Respiration, Vol. 88, Iss. 3, 2014-08 ,pp. : 199-207

Karger

Access to resources Recommend Favorite